Devonian Health Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Devonian Health Group şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-8.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-8.4%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Does Devonian Health Group's (CVE:GSD) CEO Salary Compare Well With Industry Peers?

Mar 02

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: GSD şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: GSD şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Devonian Health Group Piyasaya Karşı Temettü Getirisi

GSD temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (GSD)	n/a
Pazarın Alt %25'i (CA)	1.8%
Pazarın En İyi %25'i (CA)	6.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (GSD) (3 yıla kadar)	n/a

Önemli Temettü: GSD şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, GSD şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: GSD şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: GSD herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Devonian Health Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Devonian Health Group Inc. Announces the Resignation of Colette Laurin as Interim Chief Financial Officer, Effective January 5, 2025

Third quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.011 loss in 3Q 2023)

Devonian Health Group Inc. Appoints André P. Boulet to Chairman of the Board and Chief Operating Officer

Second quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.008 loss in 2Q 2023)

Devonian Health Group Inc. announced that it has received CAD 0.2238 million in funding

Devonian Health Group Inc., Annual General Meeting, Feb 20, 2024

Devonian Health Group Inc. Announces CEO Changes

Full year 2023 earnings released: CA$0.034 loss per share (vs CA$0.026 loss in FY 2022)

Devonian Health Group Inc. Files Patent Cooperation Treaty (PCT) Application for Thykamine™? in Wound Healing

Devonian Health Group Inc. announced that it has received CAD 0.5 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.006 loss in 3Q 2022)

Devonian Health Group Inc. announced that it has received CAD 1.199665 million in funding

Devonian Health Group Inc. announced that it expects to receive CAD 5 million in funding

Devonian Health Group Announces Presentation of ThykamineTM Efficacy Results in Atopic Dermatitis at the World Congress of Dermatology and Provides ThykamineTM Clinical Development Program Update

Devonian Health Group Announces the Appointment of New Board Members

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 2Q 2022)

Is Devonian Health Group (CVE:GSD) A Risky Investment?

Devonian Health Group Inc., Annual General Meeting, Mar 17, 2023

Devonian Health Group Inc. Announces Executive Changes

Is Devonian Health Group (CVE:GSD) Using Debt In A Risky Way?

Full year 2022 earnings released

High number of new directors

Devonian Health Group Inc. to Present ThykamineTM Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases

Devonian Health Group Announces Peer-Reviewed Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Journal of Drugs in Dermatology

High number of new directors

Devonian Health Group Inc. Announces CEO Changes

Is Devonian Health Group (CVE:GSD) Weighed On By Its Debt Load?

Third quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.01 loss in 3Q 2021)

High number of new directors

Devonian Health Group Announces the Journal of Drugs in Dermatology Acceptance for Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Atopic Dermatitis

High number of new directors

Does Devonian Health Group (CVE:GSD) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 2Q 2021)

High number of new and inexperienced directors

Devonian Health Group Inc. Approves Board Appointments

Devonian Health Group Inc. announced that it has received CAD 10.034299 million in funding

Full year 2021 earnings: Revenues in line with analyst expectations

Devonian Health Group Inc. announced that it has received CAD 1.06264 million in funding

Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.014 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.019 loss in 2Q 2020)

Does Devonian Health Group's (CVE:GSD) CEO Salary Compare Well With Industry Peers?

Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of ThykamineTM in Adult Patients with Mild-to-Moderate Atopic Dermatitis

New 90-day high: CA$0.29

Devonian Health Group Inc. Appoints Erick Shield as Director

New 90-day high: CA$0.28

Devonian Health Group Inc. announced that it has received CAD 1.212 million in funding

Devonian Health Group Inc., Annual General Meeting, Jan 27, 2021

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin